- Home
- TRDA vs PHAT Comparison
TRDA vs PHAT Comparison
Compare TRDA & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRDA
- PHAT
- Stock Information
- Founded
- TRDA 2016
- PHAT 2018
- Country
- TRDA United States
- PHAT United States
- Employees
- TRDA N/A
- PHAT N/A
- Industry
- TRDA Biotechnology: Pharmaceutical Preparations
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- TRDA Health Care
- PHAT Health Care
- Exchange
- TRDA Nasdaq
- PHAT Nasdaq
- Market Cap
- TRDA 336.6M
- PHAT 289.0M
- IPO Year
- TRDA 2021
- PHAT 2019
- Fundamental
- Price
- TRDA $7.97
- PHAT $4.57
- Analyst Decision
- TRDA Strong Buy
- PHAT Strong Buy
- Analyst Count
- TRDA 3
- PHAT 4
- Target Price
- TRDA $25.67
- PHAT $16.25
- AVG Volume (30 Days)
- TRDA 144.1K
- PHAT 2.2M
- Earning Date
- TRDA 05-08-2025
- PHAT 05-01-2025
- Dividend Yield
- TRDA N/A
- PHAT N/A
- EPS Growth
- TRDA N/A
- PHAT N/A
- EPS
- TRDA 0.61
- PHAT N/A
- Revenue
- TRDA $172,220,000.00
- PHAT $81,859,000.00
- Revenue This Year
- TRDA N/A
- PHAT $195.45
- Revenue Next Year
- TRDA N/A
- PHAT $106.76
- P/E Ratio
- TRDA $12.53
- PHAT N/A
- Revenue Growth
- TRDA 5.74
- PHAT 3055.70
- 52 Week Low
- TRDA $7.10
- PHAT $2.21
- 52 Week High
- TRDA $21.79
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- TRDA 42.48
- PHAT 55.71
- Support Level
- TRDA $7.55
- PHAT $4.05
- Resistance Level
- TRDA $8.05
- PHAT $4.35
- Average True Range (ATR)
- TRDA 0.39
- PHAT 0.37
- MACD
- TRDA -0.00
- PHAT 0.12
- Stochastic Oscillator
- TRDA 21.73
- PHAT 87.71
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.